HomeTOP STORIESAstraZeneca reports disappointing Phase 3 data for lung cancer ADC AstraZeneca reports disappointing Phase 3 data for lung cancer ADC By pvadmin September 9, 2024 FacebookTwitterPinterestWhatsApp [#item_full_content] Previous articleUber’s Khosrowshahi sees significant growth potential in AV, sponsor listing, plans for buybacksNext articleCleveland Browns Quarterback Deshaun Watson Accused of Sexual Assault latest articles Heading Toward Midterms, the G.O.P. Continues to Slip HSBC taps Brendan Nelson as new chairman to replace Mark Tucker Asia markets trade mixed on rate cut bets, Australian stocks flat despite stronger annual GDP Forward Industries partners with Sanctum to launch fwdSOL liquid staking token Australian economy extends growth streak despite softer-than-expected GDP in Q3 Earnings Snapshot: Marvell Technology tops FQ3 estimates; forecasts over 40% full-year revenue growth, FQ4 growth remains robust explore more Heading Toward Midterms, the G.O.P. Continues to Slip HSBC taps Brendan Nelson as new chairman to replace Mark Tucker Asia markets trade mixed on rate cut bets, Australian stocks flat despite stronger annual GDP Forward Industries partners with Sanctum to launch fwdSOL liquid staking token Australian economy extends growth streak despite softer-than-expected GDP in Q3 Earnings Snapshot: Marvell Technology tops FQ3 estimates; forecasts over 40% full-year revenue growth, FQ4 growth remains robust
